These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36252265)

  • 1. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
    England JT; Gupta V
    Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
    Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
    Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
    Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
    Saha C; Harrison C
    Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
    Harrison CN; Mesa R; Talpaz M; Al-Ali HK; Xicoy B; Passamonti F; Palandri F; Benevolo G; Vannucchi AM; Mediavilla C; Iurlo A; Kim I; Rose S; Brown P; Hernandez C; Wang J; Kiladjian JJ
    Lancet Haematol; 2024 Oct; 11(10):e729-e740. PubMed ID: 39265613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
    Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian JJ; Vannucchi AM; Verstovsek S; Colak G; Dey D; Harrison C
    Blood Adv; 2023 Sep; 7(18):5421-5432. PubMed ID: 37530627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
    Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH
    Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
    Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
    Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
    Tiribelli M; Morelli G; Bonifacio M
    Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
    Tremblay D; Mascarenhas J
    Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
    Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
    Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
    Mascarenhas J; Harrison C; Schuler TA; Liassou D; Garretson M; Miller TA; Mahadevan S; McBride A; Tang D; DeGutis IS; Abraham P; Kish J; Feinberg BA; Gerds AT
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):122-132. PubMed ID: 37839939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of JAK kinase inhibitors for the treatment of myelofibrosis.
    Coltro G; Vannucchi AM
    Expert Opin Drug Saf; 2021 Feb; 20(2):139-154. PubMed ID: 33327810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety considerations when treating myelofibrosis.
    O'Sullivan JM; McLornan DP; Harrison CN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.